Taisho Pharmaceutical Holdings Co., Ltd.
Other OTCTotal Valuation
Taisho Pharmaceutical Holdings Co., Ltd. carries a market capitalization of 18.13B, placing it among publicly traded companies globally. Its enterprise value stands at -241.16B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 18.13B |
| Enterprise Value | -241.16B |
Share Statistics
Taisho Pharmaceutical Holdings Co., Ltd. currently has 3.00 shares outstanding.
| Shares Outstanding | 3.00 |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Taisho Pharmaceutical Holdings Co., Ltd. trades at a trailing price-to-earnings ratio of 0.00. The price-to-sales ratio is -NaN, and the price-to-book ratio stands at -NaN.
| PE Ratio | 0.00 |
| PS Ratio | -NaN |
| PB Ratio | -NaN |
| P/TBV Ratio | -NaN |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
Financial Position
Taisho Pharmaceutical Holdings Co., Ltd. maintains a current ratio of 5.16, meaning it holds 5.2x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 5.16 |
| Quick Ratio | 3.30 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | 87.55 |
Financial Efficiency
Taisho Pharmaceutical Holdings Co., Ltd. posts a return on equity of 1.13 and a return on invested capital of 1.44.
| Return on Equity (ROE) | 1.13 |
| Return on Assets (ROA) | 0.86 |
| Return on Invested Capital (ROIC) | 1.44 |
| Return on Capital Employed (ROCE) | 0.79 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 2.48 |
Taxes
Over the trailing twelve months, Taisho Pharmaceutical Holdings Co., Ltd. has paid 6.17B in income taxes, reflecting an effective tax rate of 36.10.
| Income Tax | 6.17B |
| Effective Tax Rate | 36.10 |
Stock Price Statistics
Taisho Pharmaceutical Holdings Co., Ltd.'s stock has gained approximately 47.75726% over the past 52 weeks. The 50-day moving average sits at 12.20, while the 200-day moving average is 12.93.
| Beta (5Y) | N/A |
| 52-Week Price Change | 47.75726% |
| 50-Day Moving Average | 12.20 |
| 200-Day Moving Average | 12.93 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Taisho Pharmaceutical Holdings Co., Ltd. generated 320.39B in revenue and converted that into 8.42B in net income, yielding earnings per share of 909.75M. EBITDA reached 18.91B, while operating income came in at 18.91B.
| Revenue | 320.39B |
| Gross Profit | 183.16B |
| Operating Income | 18.91B |
| Pretax Income | 17.08B |
| Net Income | 8.42B |
| EBITDA | 18.91B |
| EBIT | 18.91B |
| Earnings Per Share (EPS) | 909.75M |
Balance Sheet
Total book value stands at 745.86B, with working capital of 335.95B providing operational flexibility.
| Cash & Cash Equivalents | 266.37B |
| Total Debt | N/A |
| Net Debt | -246.07B |
| Equity (Book Value) | 745.86B |
| Book Value Per Share | 62.15B |
| Working Capital | 335.95B |
Margins
Taisho Pharmaceutical Holdings Co., Ltd. operates with a gross margin of 57.17, reflecting its pricing power and cost economics. The operating margin of 5.90 and net profit margin of 2.63 provide insight into operational efficiency.
| Gross Margin | 57.17 |
| Operating Margin | 5.90 |
| Pretax Margin | 5.33 |
| Profit Margin | 2.63 |
| EBITDA Margin | 5.90 |
Scores
Taisho Pharmaceutical Holdings Co., Ltd. posts an Altman Z-Score of 2.36, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 2.36 |